iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announced it will report fiscal 2022 second quarter financial results on February 14, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results and future corporate updates. iBio specializes in next-generation biopharmaceuticals, utilizing its innovative FastPharming Manufacturing System® for sustainable, plant-based biologics. The company aims to advance treatments for cancers and other diseases through high-quality monoclonal antibodies and proteins.

Positive

• iBio's FastPharming System is a pioneering technology for sustainable biopharmaceutical manufacturing.
• The company's focus on developing proprietary biopharmaceuticals for cancers, fibrotic and infectious diseases indicates a strong pipeline potential.

Negative

• None.

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System^®, announced today that it will report its fiscal 2022 second quarter financial results after market close on Monday, February 14, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference ID: 3527478.

About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System^® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

FAQ

When will iBio report its fiscal 2022 second quarter financial results?

iBio will report its fiscal 2022 second quarter financial results on February 14, 2022, after market close.

What time will the iBio conference call take place?

The iBio management will host a conference call at 4:30 PM Eastern Time on February 14, 2022.

What is iBio's FastPharming Manufacturing System?

The FastPharming Manufacturing System is an innovative, sustainable, plant-based biopharmaceutical manufacturing technology developed by iBio.

What diseases is iBio developing treatments for?

iBio is developing proprietary biopharmaceuticals for the treatment of cancers, fibrotic diseases, and infectious diseases.